Company Shares of Sangamo BioSciences (NASDAQ:SGMO) Rally 2.66%

Sangamo BioSciences (NASDAQ:SGMO) has been under a strong bear grip, hence the stock is down -5.56% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 1.36% in the past 1 week. The stock has risen by 2.66% in the past week indicating that the buyers are active at lower levels, but the stock is down -4.04% in the past 4 weeks.

The company shares have dropped -40.69% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $11.00 and the one year low was seen on Feb 12, 2016. The 50-Day Moving Average price is $6.26 and the 200 Day Moving Average price is recorded at $6.35.

The stock has recorded a 20-day Moving Average of 4.98% and the 50-Day Moving Average is 0.32%.


Sangamo BioSciences (NASDAQ:SGMO): stock turned positive on Friday. Though the stock opened at $6.12, the bulls momentum made the stock top out at $6.265 level for the day. The stock recorded a low of $6.0299 and closed the trading day at $6.18, in the green by 1.31%. The total traded volume for the day was 819,789. The stock had closed at $6.1 in the previous days trading.

In an insider trading activity, Lanphier Edward O Ii, director officer (President & CEO) of Sangamo Biosciences Inc, unloaded 25,000 shares at an average price of $10.43 on July 15, 2015. The total amount of the transaction was worth $260,750, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Companys lead ZFP Therapeutic SB-728-T, a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Companys clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS, SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimers disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.